RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress

Roche (RHHBY) presented compelling new clinical data for its ophthalmology drug Vabysmo at the Euretina Congress, with the AVONELLE-X study affirming sustained efficacy and durability over four years in nAMD, allowing extended dosing for nearly 80% of patients, and the SALWEEN study showing significant vision gains and lesion resolution in polypoidal choroidal vasculopathy (PCV). This robust performance propelled Vabysmo sales up 18% to CHF 2.1 billion in H1 2025, intensifying its competitive pressure on Regeneron's Eylea, and was a primary driver for Roche's pharmaceutical division achieving 10% sales growth to CHF 24 billion, contributing to a 25% year-to-date share increase despite some pipeline setbacks.

Analysis

Roche (RHHBY) has presented compelling clinical data that reinforces the competitive superiority and long-term commercial potential of its ophthalmology drug, Vabysmo. The four-year data from the AVONELLE-X extension study confirms sustained efficacy and durability in nAMD, with nearly 80% of patients achieving extended dosing intervals of three to four months—a significant advantage in patient convenience and a key differentiator against competitors. Furthermore, the SALWEEN study demonstrates strong efficacy in polypoidal choroidal vasculopathy (PCV), a subtype of nAMD prevalent in Asia, with over 60% of patients achieving complete lesion resolution, opening a crucial growth avenue. This clinical success is directly translating into commercial momentum, evidenced by Vabysmo's 18% sales growth to CHF 2.1 billion in the first half of 2025, which has been instrumental in the Pharmaceutical Division's overall 10% revenue growth to CHF 24 billion. This performance is a primary factor behind the stock's 25% year-to-date appreciation, significantly outpacing the industry's 1.7% growth, and is exerting considerable pressure on Regeneron's competing drug, Eylea. However, this positive narrative must be balanced against headwinds, including a noted pipeline setback with the astegolimab Phase III study failure and disappointing performance from the Diagnostics division.

Key Decisions for Investors

• Investors should view the latest Vabysmo data as a strong validation of its best-in-class profile, which is likely to continue driving market share gains from Regeneron's Eylea and support Roche's near-term revenue growth.
• Monitor the competitive landscape closely, particularly the market adoption and pricing of Regeneron's higher-dose Eylea HD, as this represents the most direct threat to Vabysmo's growth trajectory.
• While the pharmaceutical division shows robust health driven by key drugs like Vabysmo, investors must weigh this against the disclosed underperformance in the Diagnostics division and recent pipeline setbacks to maintain a balanced assessment of Roche's overall valuation.